Flu Vaccine for Secondary Prevention of Coronary Events

Published Online: Tuesday, March 22, 2011
Follow Pharmacy_Times:
This video presentation discusses the results of a new study that provides further evidence that influenza vaccine reduces major cardiovascular events in patients hospitalized for acute coronary syndrome.

Click here to access this third-party resource.
Related Articles
The FDA has granted priority review to expand the use of AstraZeneca’s ticagrelor (Brilinta).
The FDA today approved a new cough and cold treatment that is also intended for adults with symptoms related to upper respiratory allergies.
Four fast-acting liquid Mucinex medicines have been voluntarily recalled by RB due to mislabeling.
Phenylephrine hydrochloride is a recognized contact allergen with symptoms remarkably similar to those of a cold.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$